5CCM

Crystal structure of SMYD3 with SAM and EPZ030456

Summary for 5CCM

Entry DOI	10.2210/pdb5ccm/pdb
Related	5CCL
Descriptor	Histone-lysine N-methyltransferase SMYD3, ZINC ION, S-ADENOSYLMETHIONINE, ... (5 entities in total)
Functional Keywords	protein-inhibitor complex, methyltransferase, epigenetics, drug discovery, transferase-transferase inhibitor complex, transferase/transferase inhibitor
Biological source	Homo sapiens (Human)
Cellular location	Cytoplasm : Q9H7B4
Total number of polymer chains	1
Total formula weight	50316.89
Authors	Boriack-Sjodin, P.A. (deposition date: 2015-07-02, release date: 2015-09-09, Last modification date: 2024-03-06)
Primary citation	Mitchell, L.H.,Boriack-Sjodin, P.A.,Smith, S.,Thomenius, M.,Rioux, N.,Munchhof, M.,Mills, J.E.,Klaus, C.,Totman, J.,Riera, T.V.,Raimondi, A.,Jacques, S.L.,West, K.,Foley, M.,Waters, N.J.,Kuntz, K.W.,Wigle, T.J.,Scott, M.P.,Copeland, R.A.,Smith, J.J.,Chesworth, R. Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 Inhibitor. Acs Med.Chem.Lett., 7:134-138, 2016 Cited by PubMed: 26985287 DOI: 10.1021/acsmedchemlett.5b00272 PDB entries with the same primary citation
Experimental method	X-RAY DIFFRACTION (2.3 Å)

Structure validation